Pharmacogenomics Panel
Tests how your genes affect drug metabolism — enabling personalized medication selection and dosing.
Optimal Range
Variants in CYP2D6, CYP2C19, CYP3A4, etc.
Why It Matters
Genetic variants in drug-metabolizing enzymes mean the same medication can be effective, useless, or toxic depending on your genotype. Pharmacogenomic testing prevents adverse drug reactions and optimizes treatment — especially for statins, antidepressants, and blood thinners.
Understanding Pharmacogenomics Panel
Pharmacogenomics is the science of how your genetic makeup affects your response to medications. The cytochrome P450 (CYP) enzyme family is responsible for metabolizing approximately 75% of all prescription drugs. Genetic variants in these enzymes create four metabolizer phenotypes: poor metabolizers (drug accumulates to potentially toxic levels), intermediate metabolizers, normal (extensive) metabolizers, and ultra-rapid metabolizers (drug is cleared too quickly to be effective).
The clinical implications are striking. A poor CYP2D6 metabolizer taking codeine will get no pain relief (codeine requires CYP2D6 to be converted to morphine), while an ultra-rapid metabolizer may experience dangerous morphine levels from a standard dose. CYP2C19 variants affect the effectiveness of clopidogrel (Plavix) — poor metabolizers are at increased risk of stent thrombosis and cardiovascular events. Statin myopathy risk is strongly associated with SLCO1B1 variants, and HLA-B*57:01 testing prevents life-threatening hypersensitivity to abacavir (an HIV medication).
The most clinically impactful pharmacogenomic applications today include: antidepressant selection (CYP2D6, CYP2C19), statin tolerability (SLCO1B1), anticoagulant dosing (CYP2C9, VKORC1 for warfarin; CYP2C19 for clopidogrel), pain management (CYP2D6 for codeine/tramadol), and oncology drug dosing (DPYD for fluoropyrimidines). Testing is a one-time investment that becomes increasingly valuable as you age and your medication list grows.
Key Research
Pharmacogenomics in the clinic
Relling MV, Evans WE · Nature (2015)
Key finding: Clinical pharmacogenomics implementation has demonstrated improved drug efficacy, reduced adverse reactions, and meaningful cost savings across multiple therapeutic areas.